Saturday, 25 December 2010

Lopressor


Lopressor is a brand name of metoprolol, approved by the FDA in the following formulation(s):


LOPRESSOR (metoprolol tartrate - injectable; injection)



  • Manufacturer: NOVARTIS

    Approval date: March 30, 1984

    Strength(s): 1MG/ML [RLD][AP]

LOPRESSOR (metoprolol tartrate - tablet; oral)



  • Manufacturer: NOVARTIS

    Approved Prior to Jan 1, 1982

    Strength(s): 100MG [AB], 50MG [AB]

Has a generic version of Lopressor been approved?


Yes. The following products are equivalent to Lopressor:


metoprolol tartrate injectable; injection



  • Manufacturer: APP PHARMS

    Approval date: October 25, 2010

    Strength(s): 1MG/ML [AP]


  • Manufacturer: BEDFORD LABS

    Approval date: July 7, 2003

    Strength(s): 1MG/ML [AP]


  • Manufacturer: HIKMA FARMACEUTICA

    Approval date: May 30, 2007

    Strength(s): 1MG/ML [AP]


  • Manufacturer: HOSPIRA

    Approval date: December 21, 1993

    Strength(s): 1MG/ML [AP]


  • Manufacturer: HOSPIRA

    Approval date: July 6, 1998

    Strength(s): 1MG/ML [AP]


  • Manufacturer: HOSPIRA

    Approval date: April 29, 2008

    Strength(s): 1MG/ML [AP]


  • Manufacturer: LUITPOLD

    Approval date: September 30, 2009

    Strength(s): 1MG/ML [AP]


  • Manufacturer: LUITPOLD

    Approval date: December 29, 2010

    Strength(s): 1MG/ML [AP]


  • Manufacturer: SAGENT STRIDES

    Approval date: April 19, 2010

    Strength(s): 1MG/ML [AP]


  • Manufacturer: SANDOZ

    Approval date: October 2, 2007

    Strength(s): 1MG/ML [AP]


  • Manufacturer: WATSON LABS

    Approval date: December 21, 1993

    Strength(s): 1MG/ML [AP]

metoprolol tartrate tablet; oral



  • Manufacturer: AUROBINDO PHARMA

    Approval date: September 11, 2007

    Strength(s): 100MG [AB], 50MG [AB]


  • Manufacturer: CARACO

    Approval date: December 10, 1996

    Strength(s): 100MG [AB], 50MG [AB]


  • Manufacturer: IPCA LABS LTD

    Approval date: June 17, 2008

    Strength(s): 100MG [AB], 50MG [AB]


  • Manufacturer: MUTUAL PHARM

    Approval date: December 21, 1993

    Strength(s): 100MG [AB], 50MG [AB]


  • Manufacturer: MYLAN

    Approval date: January 16, 2004

    Strength(s): 50MG [AB]


  • Manufacturer: SANDOZ

    Approval date: March 25, 1994

    Strength(s): 100MG [AB], 50MG [AB]


  • Manufacturer: TEVA

    Approval date: January 31, 1995

    Strength(s): 100MG [AB], 50MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: May 27, 1994

    Strength(s): 100MG [AB], 50MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lopressor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Lopressor.

See also...

  • Lopressor Consumer Information (Wolters Kluwer)
  • Lopressor Tablets Consumer Information (Wolters Kluwer)
  • Lopressor Consumer Information (Cerner Multum)
  • Lopressor Advanced Consumer Information (Micromedex)
  • Lopressor Intravenous Advanced Consumer Information (Micromedex)
  • Metoprolol Consumer Information (Drugs.com)
  • Metoprolol Succinate Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Metoprolol Tartrate Consumer Information (Wolters Kluwer)
  • Metoprolol Tartrate Tablets Consumer Information (Wolters Kluwer)
  • Metoprolol Tartrate Consumer Information (Cerner Multum)
  • Metoprolol Consumer Information (Cerner Multum)
  • Metoprolol Advanced Consumer Information (Micromedex)
  • Metoprolol Intravenous Advanced Consumer Information (Micromedex)
  • Metoprolol Succinate AHFS DI Monographs (ASHP)
  • Metoprolol Tartrate AHFS DI Monographs (ASHP)

Thursday, 23 December 2010

Ciprofloxacino Ges




Ciprofloxacino Ges may be available in the countries listed below.


Ingredient matches for Ciprofloxacino Ges



Ciprofloxacin

Ciprofloxacin lactate (a derivative of Ciprofloxacin) is reported as an ingredient of Ciprofloxacino Ges in the following countries:


  • Spain

International Drug Name Search

Wednesday, 15 December 2010

TDP




TDP may be available in the countries listed below.


Ingredient matches for TDP



Diclofenac

Diclofenac potassium salt (a derivative of Diclofenac) is reported as an ingredient of TDP in the following countries:


  • India

Thiocolchicoside

Thiocolchicoside is reported as an ingredient of TDP in the following countries:


  • India

International Drug Name Search

Wednesday, 8 December 2010

Loperamide EG




Loperamide EG may be available in the countries listed below.


Ingredient matches for Loperamide EG



Loperamide

Loperamide hydrochloride (a derivative of Loperamide) is reported as an ingredient of Loperamide EG in the following countries:


  • Belgium

International Drug Name Search

Monday, 6 December 2010

Domoso




In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Domoso



Dimethyl Sulfoxide

Dimethyl Sulfoxide is reported as an ingredient of Domoso in the following countries:


  • Australia

  • New Zealand

  • United States

International Drug Name Search

Saturday, 4 December 2010

Tetraicin




Tetraicin may be available in the countries listed below.


Ingredient matches for Tetraicin



Tetracycline

Tetracycline hydrochloride (a derivative of Tetracycline) is reported as an ingredient of Tetraicin in the following countries:


  • Bangladesh

International Drug Name Search

Wednesday, 1 December 2010

Pivampicilline




Pivampicilline may be available in the countries listed below.


Ingredient matches for Pivampicilline



Pivampicillin

Pivampicilline (DCF) is also known as Pivampicillin (Rec.INN)

International Drug Name Search

Glossary

DCFDénomination Commune Française
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Sunday, 21 November 2010

Half Sinemet




Half Sinemet may be available in the countries listed below.


Ingredient matches for Half Sinemet



Carbidopa

Carbidopa monohydrate (a derivative of Carbidopa) is reported as an ingredient of Half Sinemet in the following countries:


  • United Kingdom

Levodopa

Levodopa is reported as an ingredient of Half Sinemet in the following countries:


  • United Kingdom

International Drug Name Search

Thursday, 18 November 2010

Colistin Norma




Colistin Norma may be available in the countries listed below.


Ingredient matches for Colistin Norma



Colistin Sulfate

Colistin sulphomethate sodium (a derivative of Colistin) is reported as an ingredient of Colistin Norma in the following countries:


  • Greece

International Drug Name Search

Gentlax




In the US, Gentlax (senna systemic) is a member of the drug class laxatives and is used to treat Bowel Preparation and Constipation.

US matches:

  • Gentlax

  • Gentlax S

  • Gentlax Tablet

Ingredient matches for Gentlax



Bisacodyl

Bisacodyl is reported as an ingredient of Gentlax in the following countries:


  • Canada

International Drug Name Search

Monday, 15 November 2010

Keystat




Keystat may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Keystat



Amprolium

Amprolium is reported as an ingredient of Keystat in the following countries:


  • Australia

Ethopabate

Ethopabate is reported as an ingredient of Keystat in the following countries:


  • Australia

International Drug Name Search

Saturday, 13 November 2010

Amiodarone cloridrato Bioindustria Lim




Amiodarone cloridrato Bioindustria Lim may be available in the countries listed below.


Ingredient matches for Amiodarone cloridrato Bioindustria Lim



Amiodarone

Amiodarone hydrochloride (a derivative of Amiodarone) is reported as an ingredient of Amiodarone cloridrato Bioindustria Lim in the following countries:


  • Italy

International Drug Name Search

Friday, 12 November 2010

Lansoprazole Ranbaxy




Lansoprazole Ranbaxy may be available in the countries listed below.


Ingredient matches for Lansoprazole Ranbaxy



Lansoprazole

Lansoprazole is reported as an ingredient of Lansoprazole Ranbaxy in the following countries:


  • France

International Drug Name Search

Thursday, 11 November 2010

Tiof




Tiof may be available in the countries listed below.


Ingredient matches for Tiof



Timolol

Timolol maleate (a derivative of Timolol) is reported as an ingredient of Tiof in the following countries:


  • Chile

  • Peru

International Drug Name Search

Friday, 5 November 2010

Lemod




Lemod may be available in the countries listed below.


Ingredient matches for Lemod



Methylprednisolone

Methylprednisolone is reported as an ingredient of Lemod in the following countries:


  • Serbia

International Drug Name Search

Thursday, 4 November 2010

Tachystin




Tachystin may be available in the countries listed below.


Ingredient matches for Tachystin



Dihydrotachysterol

Dihydrotachysterol is reported as an ingredient of Tachystin in the following countries:


  • Czech Republic

  • Estonia

  • Germany

  • Hungary

  • Latvia

  • Lithuania

  • Romania

  • Slovakia

International Drug Name Search

Tuesday, 26 October 2010

Glibide




Glibide may be available in the countries listed below.


Ingredient matches for Glibide



Glibenclamide

Glibenclamide is reported as an ingredient of Glibide in the following countries:


  • Taiwan

International Drug Name Search

Saturday, 23 October 2010

Calnathal TP




Calnathal TP may be available in the countries listed below.


Ingredient matches for Calnathal TP



Pentoxyverine

Pentoxyverine citrate (a derivative of Pentoxyverine) is reported as an ingredient of Calnathal TP in the following countries:


  • Japan

International Drug Name Search

Friday, 22 October 2010

Flodeneu




Flodeneu may be available in the countries listed below.


Ingredient matches for Flodeneu



Piroxicam

Piroxicam is reported as an ingredient of Flodeneu in the following countries:


  • Greece

International Drug Name Search

Wednesday, 20 October 2010

Medicillin




Medicillin may be available in the countries listed below.


Ingredient matches for Medicillin



Ampicillin

Ampicillin trihydrate (a derivative of Ampicillin) is reported as an ingredient of Medicillin in the following countries:


  • Bangladesh

Phenoxymethylpenicillin

Phenoxymethylpenicillin potassium (a derivative of Phenoxymethylpenicillin) is reported as an ingredient of Medicillin in the following countries:


  • Finland

International Drug Name Search

Urotrol




In the US, Urotrol (oxybutynin systemic) is a member of the drug class urinary antispasmodics and is used to treat Dysuria, Hyperhidrosis, Overactive Bladder, Prostatitis and Urinary Incontinence.

US matches:

  • Urotrol

Ingredient matches for Urotrol



Propiverine

Propiverine hydrochloride (a derivative of Propiverine) is reported as an ingredient of Urotrol in the following countries:


  • Taiwan

Tolterodine

Tolterodine tartrate (a derivative of Tolterodine) is reported as an ingredient of Urotrol in the following countries:


  • Spain

International Drug Name Search

Tuesday, 19 October 2010

Glauko Biciron




Glauko Biciron may be available in the countries listed below.


Ingredient matches for Glauko Biciron



Pilocarpine

Pilocarpine hydrochloride (a derivative of Pilocarpine) is reported as an ingredient of Glauko Biciron in the following countries:


  • Germany

International Drug Name Search

Monday, 18 October 2010

Prorenal




Prorenal may be available in the countries listed below.


Ingredient matches for Prorenal



Limaprost

Limaprost alfadex (a derivative of Limaprost) is reported as an ingredient of Prorenal in the following countries:


  • Japan

International Drug Name Search

Thursday, 7 October 2010

Burinex med Kaliumklorid




Burinex med Kaliumklorid may be available in the countries listed below.


Ingredient matches for Burinex med Kaliumklorid



Bumetanide

Bumetanide is reported as an ingredient of Burinex med Kaliumklorid in the following countries:


  • Denmark

Potassium Chloride

Potassium Chloride is reported as an ingredient of Burinex med Kaliumklorid in the following countries:


  • Denmark

International Drug Name Search

Monday, 4 October 2010

Paranox




Paranox may be available in the countries listed below.


Ingredient matches for Paranox



Paracetamol

Paracetamol is reported as an ingredient of Paranox in the following countries:


  • Turkey

International Drug Name Search

Saturday, 25 September 2010

Omnistad




Omnistad may be available in the countries listed below.


Ingredient matches for Omnistad



Tamsulosin

Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Omnistad in the following countries:


  • Denmark

International Drug Name Search

Verapamil Merck




Verapamil Merck may be available in the countries listed below.


Ingredient matches for Verapamil Merck



Verapamil

Verapamil hydrochloride (a derivative of Verapamil) is reported as an ingredient of Verapamil Merck in the following countries:


  • Italy

International Drug Name Search

Monday, 20 September 2010

Neguvon




Neguvon may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Neguvon



Metrifonate

Metrifonate is reported as an ingredient of Neguvon in the following countries:


  • Australia

  • Italy

  • Portugal

International Drug Name Search

Sunday, 19 September 2010

Vetaket




In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Vetaket



Ketamine

Ketamine hydrochloride (a derivative of Ketamine) is reported as an ingredient of Vetaket in the following countries:


  • United States

International Drug Name Search

Saturday, 18 September 2010

Hibitane Champ




Hibitane Champ may be available in the countries listed below.


Ingredient matches for Hibitane Champ



Chlorhexidine

Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Hibitane Champ in the following countries:


  • France

International Drug Name Search

Monday, 6 September 2010

Clonid-Ophtal




Clonid-Ophtal may be available in the countries listed below.


Ingredient matches for Clonid-Ophtal



Clonidine

Clonidine hydrochloride (a derivative of Clonidine) is reported as an ingredient of Clonid-Ophtal in the following countries:


  • Germany

International Drug Name Search

Sunday, 5 September 2010

OxyContin


OxyContin is a brand name of oxycodone, approved by the FDA in the following formulation(s):


OXYCONTIN (oxycodone hydrochloride - tablet, extended release; oral)



  • Manufacturer: PURDUE PHARMA LP

    Approval date: April 5, 2010

    Strength(s): 10MG, 15MG, 20MG, 30MG, 40MG [RLD], 60MG, 80MG

Has a generic version of OxyContin been approved?


No. There is currently no therapeutically equivalent version of OxyContin available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of OxyContin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Controlled release oxycodone compositions
    Patent 5,508,042
    Issued: April 16, 1996
    Inventor(s): Oshlack; Benjamin & Chasin; Mark & Minogue; John J. & Kaiko; Robert F.
    Assignee(s): Euro-Celtigue, S.A.
    A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e. every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed.
    Patent expiration dates:

    • April 16, 2013
      ✓ 
      Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME




  • Hot-melt extrudable pharmaceutical formulation
    Patent 6,488,963
    Issued: December 3, 2002
    Inventor(s): James W.; McGinity & Feng; Zhang
    Assignee(s): The University of Texas System
    The present invention relates to pharmaceutical formulations comprising a hot-melt extrudable mixture of a therapeutic compound and a high molecular weight poly(ethylene oxide) in an essentially non-film like preparation. In some embodiments, the formulation further comprises poly(ethylene glycol). The present invention also includes efficient methods for hot-melt extruding pharmaceutical formulations in essentially non-film preparations.
    Patent expiration dates:

    • June 24, 2017
      ✓ 
      Drug product




  • Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
    Patent 7,674,799
    Issued: March 9, 2010
    Inventor(s): Chapman; Robert & Rider; Lonn S. & Hong; Qi & Kyle; Donald & Kupper; Robert
    Assignee(s): Purdue Pharma L.P.
    In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Patent expiration dates:

    • March 30, 2025
      ✓ 
      Drug product




  • Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
    Patent 7,674,800
    Issued: March 9, 2010
    Inventor(s): Chapman; Robert & Rider; Lonn S. & Hong; Qi & Kyle; Donald & Kupper; Robert
    Assignee(s): Purdue Pharma L.P.
    In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Patent expiration dates:

    • March 30, 2025
      ✓ 
      Drug substance




  • Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
    Patent 7,683,072
    Issued: March 23, 2010
    Inventor(s): Chapman; Robert & Rider; Lonn S. & Hong; Qi & Kyle; Donald & Kupper; Robert
    Assignee(s): Purdue Pharma L.P.
    In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Patent expiration dates:

    • March 30, 2025
      ✓ 
      Drug substance




  • Abuse-proofed dosage system
    Patent 7,776,314
    Issued: August 17, 2010
    Inventor(s): Bartholomäus; Johannes & Kugelmann; Heinrich
    Assignee(s): Grunenthal GmbH
    The invention relates to a solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.
    Patent expiration dates:

    • April 19, 2025
      ✓ 
      Drug product




  • Abuse-proofed dosage form
    Patent 8,114,383
    Issued: February 14, 2012
    Inventor(s): Bartholomäus; Johannes & Kugelmann; Heinrich & Arkenau-Marić; Elisabeth
    Assignee(s): Gruenenthal GmbH
    The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
    Patent expiration dates:

    • October 10, 2024
      ✓ 
      Drug product



See also...

  • Oxycontin Consumer Information (Drugs.com)
  • OxyContin Sustained-Release Tablets Consumer Information (Wolters Kluwer)
  • OxyContin Consumer Information (Cerner Multum)
  • Oxycontin Advanced Consumer Information (Micromedex)
  • Oxycodone Consumer Information (Drugs.com)
  • Oxycodone Consumer Information (Wolters Kluwer)
  • Oxycodone Concentrate Consumer Information (Wolters Kluwer)
  • Oxycodone Solution Consumer Information (Wolters Kluwer)
  • Oxycodone Sustained-Release Tablets Consumer Information (Wolters Kluwer)
  • Oxycodone Consumer Information (Cerner Multum)
  • Oxy IR Advanced Consumer Information (Micromedex)
  • Oxycontin CR Advanced Consumer Information (Micromedex)
  • Oxycodone Advanced Consumer Information (Micromedex)
  • Oxycodone AHFS DI Monographs (ASHP)
  • Oxycodone Hydrochloride AHFS DI Monographs (ASHP)

Thursday, 2 September 2010

Metofin




Metofin may be available in the countries listed below.


Ingredient matches for Metofin



Metoprolol

Metoprolol succinate (a derivative of Metoprolol) is reported as an ingredient of Metofin in the following countries:


  • India

International Drug Name Search

Saturday, 28 August 2010

Phloroglucinol EG




Phloroglucinol EG may be available in the countries listed below.


Ingredient matches for Phloroglucinol EG



Phloroglucinol

Phloroglucinol is reported as an ingredient of Phloroglucinol EG in the following countries:


  • France

International Drug Name Search

Monday, 23 August 2010

Hydroxyamphétamine




Hydroxyamphétamine may be available in the countries listed below.


Ingredient matches for Hydroxyamphétamine



Hydroxyamfetamine

Hydroxyamphétamine (DCF) is also known as Hydroxyamfetamine (Rec.INN)

International Drug Name Search

Glossary

DCFDénomination Commune Française
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Saturday, 21 August 2010

Aluminum Chlorohydrate




Aluminum Chlorohydrate may be available in the countries listed below.


Ingredient matches for Aluminum Chlorohydrate



Aluminium Chlorohydrate

Aluminum Chlorohydrate (USAN) is also known as Aluminium Chlorohydrate

International Drug Name Search

Glossary

USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Sunday, 15 August 2010

Flogol




Flogol may be available in the countries listed below.


Ingredient matches for Flogol



Etofenamate

Etofenamate is reported as an ingredient of Flogol in the following countries:


  • Argentina

International Drug Name Search

Flemgo




Flemgo may be available in the countries listed below.


Ingredient matches for Flemgo



Carbocisteine

Carbocisteine is reported as an ingredient of Flemgo in the following countries:


  • South Africa

International Drug Name Search

Wednesday, 11 August 2010

Salbulair N Autohaler




Salbulair N Autohaler may be available in the countries listed below.


Ingredient matches for Salbulair N Autohaler



Salbutamol

Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Salbulair N Autohaler in the following countries:


  • Germany

International Drug Name Search

Tuesday, 10 August 2010

Azucurenin S




Azucurenin S may be available in the countries listed below.


Ingredient matches for Azucurenin S



Glutamine

Glutamine is reported as an ingredient of Azucurenin S in the following countries:


  • Japan

Sodium Gualenate

Sodium Gualenate is reported as an ingredient of Azucurenin S in the following countries:


  • Japan

International Drug Name Search

Friday, 6 August 2010

Ralinet




Ralinet may be available in the countries listed below.


Ingredient matches for Ralinet



Loratadine

Loratadine is reported as an ingredient of Ralinet in the following countries:


  • Greece

International Drug Name Search

Sunday, 18 July 2010

Azibiotic




Azibiotic may be available in the countries listed below.


Ingredient matches for Azibiotic



Azithromycin

Azithromycin is reported as an ingredient of Azibiotic in the following countries:


  • Dominican Republic

International Drug Name Search

Tuesday, 13 July 2010

Amoxicilline / Acide Clavulanique Mylan Enfants




Amoxicilline/Acide Clavulanique Mylan Enfants may be available in the countries listed below.


Ingredient matches for Amoxicilline/Acide Clavulanique Mylan Enfants



Amoxicillin

Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Amoxicilline/Acide Clavulanique Mylan Enfants in the following countries:


  • France

Clavulanate

Clavulanic Acid potassium (a derivative of Clavulanic Acid) is reported as an ingredient of Amoxicilline/Acide Clavulanique Mylan Enfants in the following countries:


  • France

International Drug Name Search

Thursday, 8 July 2010

Pulvo Insectol




Pulvo Insectol may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Pulvo Insectol



Bioallethrin

Bioallethrin is reported as an ingredient of Pulvo Insectol in the following countries:


  • France

International Drug Name Search

Monday, 5 July 2010

Mino Aleviatin




Mino Aleviatin may be available in the countries listed below.


Ingredient matches for Mino Aleviatin



Trimethadione

Trimethadione is reported as an ingredient of Mino Aleviatin in the following countries:


  • Japan

International Drug Name Search

Sunday, 13 June 2010

Optivar



azelastine hydrochloride

Dosage Form: ophthalmic solution
Optivar®


azelastine hydrochloride

ophthalmic solution, 0.05%

Optivar Description


Optivar® (azelastine hydrochloride ophthalmic solution), 0.05% is a sterile ophthalmic solution containing azelastine hydrochloride, a relatively selective H1-receptor antagonist for topical administration to the eyes. Azelastine hydrochloride is a white crystalline powder with a molecular weight of 418.37. Azelastine hydrochloride is sparingly soluble in water, methanol and propylene glycol, and slightly soluble in ethanol, octanol, and glycerine. Azelastine hydrochloride is a racemic mixture with a melting point of 225°C. The chemical name for azelastine hydrochloride is (±)-1-(2H)-phthalazinone,4-[(4-chlorophenyl) methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, monohydrochloride and is represented by the following chemical structure:



Empirical chemical structure: C22H24ClN3O•HCl


Each mL of Optivar® contains: Active: 0.5 mg azelastine hydrochloride, equivalent to 0.457 mg of azelastine base; Preservative: 0.125 mg benzalkonium chloride; Inactives: disodium edetate dihydrate, hypromellose, sorbitol solution, sodium hydroxide and water for injection. It has a pH of approximately 5.0 to 6.5 and an osmolarity of approximately 271 to 312 mOsmol/L.



Optivar - Clinical Pharmacology


Azelastine hydrochloride is a relatively selective histamine H1 antagonist and an inhibitor of the release of histamine and other mediators from cells (e.g. mast cells) involved in the allergic response. Based on in-vitro studies using human cell lines, inhibition of other mediators involved in allergic reactions (e.g. leukotrienes and PAF) has been demonstrated with azelastine hydrochloride. Decreased chemotaxis and activation of eosinophils has also been demonstrated.



Pharmacokinetics and Metabolism


Absorption of azelastine following ocular administration was relatively low. A study in symptomatic patients receiving one drop of Optivar® in each eye two to four times a day (0.06 to 0.12 mg azelastine hydrochloride) demonstrated plasma concentrations of azelastine hydrochloride to generally be between 0.02 and 0.25 ng/mL after 56 days of treatment. Three of nineteen patients had quantifiable amounts of N-desmethylazelastine that ranged from 0.25–0.87 ng/mL at Day 56.


Based on intravenous and oral administration, the elimination half-life, steady-state volume of distribution and plasma clearance were 22 hours, 14.5 L/kg and 0.5 L/h/kg, respectively. Approximately 75% of an oral dose of radiolabeled azelastine hydrochloride was excreted in the feces with less than 10% as unchanged azelastine. Azelastine hydrochloride is oxidatively metabolized to the principal metabolite, N-desmethylazelastine, by the cytochrome P450 enzyme system. In-vitro studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97%, respectively.



Clinical Trials


In a conjunctival antigen challenge study, Optivar® was more effective than its vehicle in preventing itching associated with allergic conjunctivitis. Optivar® had a rapid (within 3 minutes) onset of effect and a duration of effect of approximately 8 hours for the prevention of itching.


In environmental studies, adult and pediatric patients with seasonal allergic conjunctivitis were treated with Optivar® for two to eight weeks. In these studies, Optivar® was more effective than its vehicle in relieving itching associated with allergic conjunctivitis.



Indications and Usage for Optivar


Optivar® is indicated for the treatment of itching of the eye associated with allergic conjunctivitis.



Contraindications


Optivar® is contraindicated in persons with known or suspected hypersensitivity to any of its components.



Warnings


Optivar® is for ocular use only and not for injection or oral use.



Precautions



Information for Patients:


To prevent contaminating the dropper tip and solution, care should be taken not to touch any surface, the eyelids, or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use. This product is sterile when packaged.


Patients should be advised not to wear a contact lens if their eye is red. Optivar® should not be used to treat contact lens related irritation. The preservative in Optivar®, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red, should be instructed to wait at least ten minutes after instilling Optivar® before they insert their contact lenses.



Carcinogenesis, Mutagenesis, Impairment of Fertility:


Azelastine hydrochloride administered orally for 24 months was not carcinogenic in rats and mice at doses up to 30 mg/kg/day and 25 mg/kg/day, respectively. Based on a 30 µL drop size, these doses were approximately 25,000 and 21,000 times higher than the maximum recommended ocular human use level of 0.001 mg/kg/day for a 50 kg adult.


Azelastine hydrochloride showed no genotoxic effects in the Ames test, DNA repair test, mouse lymphoma forward mutation assay, mouse micronucleus test, or chromosomal aberration test in rat bone marrow. Reproduction and fertility studies in rats showed no effects on male or female fertility at oral doses of up to 25,000 times the maximum recommended ocular human use level. At 68.6 mg/kg/day (57,000 times the maximum recommended ocular human use level), the duration of the estrous cycle was prolonged and copulatory activity and the number of pregnancies were decreased. The numbers of corpora lutea and implantations were decreased; however, the implantation ratio was not affected.



Pregnancy:


Teratogenic Effects: Pregnancy Category C. Azelastine hydrochloride has been shown to be embryotoxic, fetotoxic, and teratogenic (external and skeletal abnormalities) in mice at an oral dose of 68.6 mg/kg/day (57,000 times the recommended ocular human use level). At an oral dose of 30 mg/kg/day (25,000 times the recommended ocular human use level), delayed ossification (undeveloped metacarpus) and the incidence of 14th rib were increased in rats. At 68.6 mg/kg/day (57,000 times the maximum recommended ocular human use level) azelastine hydrochloride caused resorption and fetotoxic effects in rats. The relevance to humans of these skeletal findings noted at only high drug exposure levels is unknown.


There are no adequate and well-controlled studies in pregnant women. Optivar® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.



Nursing Mothers:


It is not known whether azelastine hydrochloride is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Optivar® is administered to a nursing woman.



Pediatric Use:


Safety and effectiveness in pediatric patients below the age of 3 have not been established.



Geriatric Use:


No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.



ADVERSE REACTIONS:


To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


In controlled multiple-dose studies where patients were treated for up to 56 days, the most frequently reported adverse reactions were transient eye burning/stinging (approximately 30%), headaches (approximately 15%) and bitter taste (approximately 10%). The occurrence of these events was generally mild.


The following events were reported in 1–10% of patients: asthma, conjunctivitis, dyspnea, eye pain, fatigue, influenza-like symptoms, pharyngitis, pruritus, rhinitis and temporary blurring. Some of these events were similar to the underlying disease being studied.



Optivar Dosage and Administration


The recommended dose is one drop instilled into each affected eye twice a day.



How is Optivar Supplied


Optivar® (azelastine hydrochloride ophthalmic solution), 0.05% is supplied as follows:

Optivar® 6 mL (NDC#0037-7025-60) solution in a translucent 10 mL HDPE container with a LDPE dropper tip and a white HDPE screw cap.



Storage


Store UPRIGHT between 2° and 25°C (36° and 77°F).


Rx Only


U.S. Patent 5,164,194


Manufactured by:

Patheon UK Ltd.

Swindon, United Kingdom

Distributed by:


MEDA Pharmaceuticals®

Meda Pharmaceuticals Inc.

Somerset, New Jersey 08873-4120


Made in United Kingdom


Rev. 4/09


OTE 91421



Package Label - Principal Display Panel – 6 mL-fill


NDC 0037-7025-60


Optivar®


azelastine hydrochloride

ophthalmic solution, 0.05%


Rx Only     6 mL – Sterile


Usual dosage: 1 drop per affected eye(s) twice daily.

See package insert for full prescribing information.

STORE UPRIGHT between 2° and 25°C (36° and 77°F).


U.S. Patent 5,164,194

Mfd by: Patheon UK Ltd. Swindon, United Kingdom


Dist by:

MEDA Pharmaceuticals ®

Meda Pharmaceuticals Inc.

Somerset, New Jersey 08873-4120


OTD 90941


Rev. 4/09


Made in United Kingdom


Exp. Date

Lot No.










Optivar 
azelastine hydrochloride  solution/ drops










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0037-7025
Route of AdministrationINTRAOCULARDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
AZELASTINE HYDROCHLORIDE (AZELASTINE)AZELASTINE HYDROCHLORIDE0.5 mg  in 1 mL






Inactive Ingredients
Ingredient NameStrength
BENZALKONIUM CHLORIDE125 ug  in 1 mL


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
10037-7025-601 BOTTLE In 1 BOXcontains a BOTTLE, PLASTIC
16 mL In 1 BOTTLE, PLASTICThis package is contained within the BOX (0037-7025-60)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02112705/22/2000


Labeler - Meda Pharmaceuticals Inc. (051229602)
Revised: 07/2010Meda Pharmaceuticals Inc.




More Optivar resources


  • Optivar Side Effects (in more detail)
  • Optivar Dosage
  • Optivar Use in Pregnancy & Breastfeeding
  • Optivar Drug Interactions
  • Optivar Support Group
  • 1 Review for Optivar - Add your own review/rating


  • Optivar Concise Consumer Information (Cerner Multum)

  • Optivar Advanced Consumer (Micromedex) - Includes Dosage Information

  • Optivar Drops MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Optivar with other medications


  • Conjunctivitis, Allergic

Monday, 7 June 2010

Benzo-Ginestryl




Benzo-Ginestryl may be available in the countries listed below.


Ingredient matches for Benzo-Ginestryl



Estradiol

Estradiol 3-benzoate (a derivative of Estradiol) is reported as an ingredient of Benzo-Ginestryl in the following countries:


  • Mexico

International Drug Name Search

Thursday, 3 June 2010

Benzylthiouracil




ATC (Anatomical Therapeutic Chemical Classification)

H03BA03

CAS registry number (Chemical Abstracts Service)

0033086-27-0

Chemical Formula

C11-H10-N2-O-S

Molecular Weight

218

Therapeutic Category

Antithyroid agent

Chemical Name

6-Benzyl-2,3-dihydro-2-thioxopyrimidin-4(1H)-one

Foreign Names

  • Benzylthiouracil (German)
  • Benzylthiouracile (French)

Generic Name

  • Benzylthiouracile (OS: DCF)

Brand Names

  • Basdene
    Bouchara-Recordati, Vietnam


  • Basdène
    Bouchara, Algeria; Bouchara, France; Bouchara-Recordati, Tunisia

International Drug Name Search

Glossary

DCFDénomination Commune Française
OSOfficial Synonym

Click for further information on drug naming conventions and International Nonproprietary Names.

Tuesday, 1 June 2010

E-Vitamin-ratiopharm




E-Vitamin-ratiopharm may be available in the countries listed below.


Ingredient matches for E-Vitamin-ratiopharm



Tocopherol, α-

Tocopherol, α- is reported as an ingredient of E-Vitamin-ratiopharm in the following countries:


  • Germany

Tocopherol, α- acetate (a derivative of Tocopherol, α-) is reported as an ingredient of E-Vitamin-ratiopharm in the following countries:


  • Germany

  • Luxembourg

International Drug Name Search

Monday, 24 May 2010

Ireven




Ireven may be available in the countries listed below.


Ingredient matches for Ireven



Venlafaxine

Venlafaxine hydrochloride (a derivative of Venlafaxine) is reported as an ingredient of Ireven in the following countries:


  • Ireland

International Drug Name Search

Friday, 14 May 2010

Youmathyle




Youmathyle may be available in the countries listed below.


Ingredient matches for Youmathyle



Sulpiride

Sulpiride is reported as an ingredient of Youmathyle in the following countries:


  • Japan

International Drug Name Search

Saturday, 8 May 2010

Akurit-4




Akurit-4 may be available in the countries listed below.


Ingredient matches for Akurit-4



Ethambutol

Ethambutol dihydrochloride (a derivative of Ethambutol) is reported as an ingredient of Akurit-4 in the following countries:


  • Myanmar

Isoniazid

Isoniazid is reported as an ingredient of Akurit-4 in the following countries:


  • Myanmar

Pyrazinamide

Pyrazinamide is reported as an ingredient of Akurit-4 in the following countries:


  • Myanmar

Rifampicin

Rifampicin is reported as an ingredient of Akurit-4 in the following countries:


  • Myanmar

International Drug Name Search

Wednesday, 28 April 2010

Voxam




Voxam may be available in the countries listed below.


Ingredient matches for Voxam



Fluvoxamine

Fluvoxamine maleate (a derivative of Fluvoxamine) is reported as an ingredient of Voxam in the following countries:


  • Australia

International Drug Name Search

Thursday, 22 April 2010

Nifuran




Nifuran may be available in the countries listed below.


Ingredient matches for Nifuran



Nitrofurantoin

Nitrofurantoin is reported as an ingredient of Nifuran in the following countries:


  • New Zealand

International Drug Name Search

Wednesday, 21 April 2010

Amilorid Mylan




Amilorid Mylan may be available in the countries listed below.


Ingredient matches for Amilorid Mylan



Amiloride

Amiloride hydrochloride dihydrate (a derivative of Amiloride) is reported as an ingredient of Amilorid Mylan in the following countries:


  • Sweden

International Drug Name Search

Thursday, 8 April 2010

Diabos




Diabos may be available in the countries listed below.


Ingredient matches for Diabos



Glibenclamide

Glibenclamide is reported as an ingredient of Diabos in the following countries:


  • Bosnia & Herzegowina

International Drug Name Search

Saturday, 3 April 2010

Spironolactone EG




Spironolactone EG may be available in the countries listed below.


Ingredient matches for Spironolactone EG



Spironolactone

Spironolactone is reported as an ingredient of Spironolactone EG in the following countries:


  • Belgium

  • France

International Drug Name Search

Sunday, 28 March 2010

Herlat L




Herlat L may be available in the countries listed below.


Ingredient matches for Herlat L



Nifedipine

Nifedipine is reported as an ingredient of Herlat L in the following countries:


  • Japan

International Drug Name Search

Saturday, 27 March 2010

Baycidal




Baycidal may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Baycidal



Triflumuron

Triflumuron is reported as an ingredient of Baycidal in the following countries:


  • Italy

  • Portugal

International Drug Name Search

Monday, 22 March 2010

Memento NF




Memento NF may be available in the countries listed below.


Ingredient matches for Memento NF



Norfloxacin

Norfloxacin is reported as an ingredient of Memento NF in the following countries:


  • Argentina

International Drug Name Search

Sunday, 21 March 2010

Tramadol-Dolgit




Tramadol-Dolgit may be available in the countries listed below.


Ingredient matches for Tramadol-Dolgit



Tramadol

Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Tramadol-Dolgit in the following countries:


  • Germany

International Drug Name Search

Friday, 19 March 2010

Coxylan




Coxylan may be available in the countries listed below.


Ingredient matches for Coxylan



Meloxicam

Meloxicam is reported as an ingredient of Coxylan in the following countries:


  • Guatemala

  • Mexico

International Drug Name Search

Sunday, 7 March 2010

Bay-O-Pet Cats




Bay-O-Pet Cats may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Bay-O-Pet Cats



Praziquantel

Praziquantel is reported as an ingredient of Bay-O-Pet Cats in the following countries:


  • Australia

Pyrantel

Pyrantel embonate (a derivative of Pyrantel) is reported as an ingredient of Bay-O-Pet Cats in the following countries:


  • Australia

International Drug Name Search

Saturday, 6 March 2010

Duet DHA


Generic Name: prenatal multivitamins (PRE nay tal VYE ta mins)

Brand Names: Advance Care Plus, Bright Beginnings, Cavan Folate, Cavan One, Cavan-Heme OB, Cenogen Ultra, CitraNatal Rx, Co Natal FA, Complete Natal DHA, Complete-RF, CompleteNate, Concept OB, Docosavit, Dualvit OB, Duet, Edge OB, Elite OB 400, Femecal OB, Folbecal, Folcaps Care One, Folivan-OB, Foltabs, Gesticare, Icar Prenatal, Icare Prenatal Rx, Inatal Advance, Infanate DHA, Kolnatal DHA, Lactocal-F, Marnatal-F, Maternity, Maxinate, Mission Prenatal, Multi-Nate 30, Multinatal Plus, Nata 29 Prenatal, Natachew, Natafort, Natelle, Neevo, Nestabs, Nexa Select with DHA, Novanatal, NovaStart, O-Cal Prenatal, OB Complete, OB Natal One, Ob-20, Obtrex DHA, OptiNate, Paire OB Plus DHA, PNV Select, PNV-Total, PR Natal 400, Pre-H-Cal, Precare, PreferaOB, Premesis Rx, PrenaCare, PrenaFirst, PrenaPlus, Prenatabs OBN, Prenatabs Rx, Prenatal 1 Plus 1, Prenatal Elite, Prenatal Multivitamins, Prenatal Plus, Prenatal S, Prenatal-U, Prenate Advanced Formula, Prenate DHA, Prenate Elite, Prenavite FC, PreNexa, PreQue 10, Previte Rx, PrimaCare, Pruet DHA, RE OB Plus DHA, Renate, RightStep, Rovin-NV, Se-Care, Se-Natal One, Se-Plete DHA, Se-Tan DHA, Select-OB, Seton ET, Strongstart, Stuart Prenatal with Beta Carotene, Tandem OB, Taron-BC, Tri Rx, TriAdvance, TriCare, Trimesis Rx, Trinate, Triveen-PRx RNF, UltimateCare Advance, Ultra-Natal, Vemavite PRX 2, VeNatal FA, Verotin-BY, Verotin-GR, Vinacal OR, Vinatal Forte, Vinate Advanced (New Formula), Vinate AZ, Vinate Care, Vinate Good Start, Vinate II (New Formula), Vinate III, Vinate One, Vitafol-OB, VitaNatal OB plus DHA, Vitaphil, Vitaphil Aide, Vitaphil Plus DHA, Vitaspire, Viva DHA, Vol-Nate, Vol-Plus, Vol-Tab Rx, Vynatal F.A., Zatean-CH, Zatean-PN


What are Duet DHA (prenatal multivitamins)?

There are many brands and forms of prenatal vitamin available and not all brands are listed on this leaflet.


Prenatal vitamins are a combination of many different vitamins that are normally found in foods and other natural sources.


Prenatal vitamins are used to provide the additional vitamins needed during pregnancy. Minerals may also be contained in prenatal multivitamins.


Prenatal vitamins may also be used for purposes not listed in this medication guide.


What is the most important information I should know about prenatal vitamins?


There are many brands and forms of prenatal vitamin available and not all brands are listed on this leaflet.


Never take more than the recommended dose of a multivitamin. Avoid taking any other multivitamin product within 2 hours before or after you take your prenatal vitamins. Taking similar vitamin products together at the same time can result in a vitamin overdose or serious side effects.

Many multivitamin products also contain minerals such as calcium, iron, magnesium, potassium, and zinc. Minerals (especially taken in large doses) can cause side effects such as tooth staining, increased urination, stomach bleeding, uneven heart rate, confusion, and muscle weakness or limp feeling. Read the label of any multivitamin product you take to make sure you are aware of what it contains.


Seek emergency medical attention if you think you have used too much of this medicine. An overdose of vitamins A, D, E, or K can cause serious or life-threatening side effects and can also harm your unborn baby. Certain minerals contained in a prenatal multivitamin may also cause serious overdose symptoms or harm to the baby if you take too much.

Overdose symptoms may include stomach pain, vomiting, diarrhea, constipation, loss of appetite, hair loss, peeling skin, tingly feeling in or around your mouth, changes in menstrual periods, weight loss, severe headache, muscle or joint pain, severe back pain, blood in your urine, pale skin, and easy bruising or bleeding.


Do not take this medication with milk, other dairy products, calcium supplements, or antacids that contain calcium. Calcium may make it harder for your body to absorb certain ingredients of the multivitamin.

What should I discuss with my healthcare provider before taking prenatal vitamins?


Many vitamins can cause serious or life-threatening side effects if taken in large doses. Do not take more of this medication than directed on the label or prescribed by your doctor.

Before taking prenatal vitamins, tell your doctor about all of your medical conditions.


You may need to continue taking prenatal vitamins if you breast-feed your baby. Ask your doctor about taking this medication while breast-feeding.

How should I take prenatal vitamins?


Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.


Never take more than the recommended dose of prenatal vitamins.

Many multivitamin products also contain minerals such as calcium, iron, magnesium, potassium, and zinc. Minerals (especially taken in large doses) can cause side effects such as tooth staining, increased urination, stomach bleeding, uneven heart rate, confusion, and muscle weakness or limp feeling. Read the label of any multivitamin product you take to make sure you are aware of what it contains.


Take your prenatal vitamin with a full glass of water.

Swallow the regular tablet or capsule whole. Do not break, chew, crush, or open it.


The chewable tablet must be chewed or allowed to dissolve in your mouth before swallowing. You may also allow the chewable tablet to dissolve in drinking water, fruit juice, or infant formula (but not milk or other dairy products). Drink this mixture right away.


Use prenatal vitamins regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.


Store at room temperature away from moisture and heat. Keep prenatal vitamins in their original container. Storing vitamins in a glass container can ruin the medication.

What happens if I miss a dose?


Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine. An overdose of vitamins A, D, E, or K can cause serious or life-threatening side effects and can also harm your unborn baby. Certain minerals contained in a prenatal multivitamin may also cause serious overdose symptoms or harm to the baby if you take too much.

Overdose symptoms may include stomach pain, vomiting, diarrhea, constipation, loss of appetite, hair loss, peeling skin, tingly feeling in or around your mouth, changes in menstrual periods, weight loss, severe headache, muscle or joint pain, severe back pain, blood in your urine, pale skin, and easy bruising or bleeding.


What should I avoid while taking prenatal vitamins?


Avoid taking any other multivitamin product within 2 hours before or after you take your prenatal vitamins. Taking similar vitamin products together at the same time can result in a vitamin overdose or serious side effects.

Avoid the regular use of salt substitutes in your diet if your multivitamin contains potassium. If you are on a low-salt diet, ask your doctor before taking a vitamin or mineral supplement.


Do not take this medication with milk, other dairy products, calcium supplements, or antacids that contain calcium. Calcium may make it harder for your body to absorb certain ingredients of the prenatal vitamin.

Prenatal vitamins side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

When taken as directed, prenatal vitamins are not expected to cause serious side effects. Less serious side effects may include:



  • upset stomach;




  • headache; or




  • unusual or unpleasant taste in your mouth.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect prenatal vitamins?


Vitamin and mineral supplements can interact with certain medications, or affect how medications work in your body. Before taking a prenatal vitamin, tell your doctor if you also use:



  • diuretics (water pills);




  • heart or blood pressure medications;




  • tretinoin (Vesanoid);




  • isotretinoin (Accutane, Amnesteen, Clavaris, Sotret);




  • trimethoprim and sulfamethoxazole (Cotrim, Bactrim, Gantanol, Gantrisin, Septra, TMP/SMX); or




  • an NSAID (non-steroidal anti-inflammatory drug) such as ibuprofen (Advil, Motrin), naproxen (Aleve, Naprosyn, Naprelan, Treximet), celecoxib (Celebrex), diclofenac (Cataflam, Voltaren), indomethacin (Indocin), meloxicam (Mobic), and others.



This list is not complete and other drugs may interact with prenatal vitamins. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Duet DHA resources


  • Duet DHA Side Effects (in more detail)
  • Duet DHA Use in Pregnancy & Breastfeeding
  • Duet DHA Drug Interactions
  • Duet DHA Support Group
  • 4 Reviews for Duet DHA - Add your own review/rating


  • Duet DHA MedFacts Consumer Leaflet (Wolters Kluwer)

  • Cal-Nate MedFacts Consumer Leaflet (Wolters Kluwer)

  • CitraNatal 90 DHA MedFacts Consumer Leaflet (Wolters Kluwer)

  • CitraNatal Assure Prescribing Information (FDA)

  • CitraNatal Harmony Prescribing Information (FDA)

  • Concept DHA Prescribing Information (FDA)

  • Docosavit Prescribing Information (FDA)

  • Duet DHA with Ferrazone MedFacts Consumer Leaflet (Wolters Kluwer)

  • Folbecal MedFacts Consumer Leaflet (Wolters Kluwer)

  • Folcal DHA Prescribing Information (FDA)

  • Folcaps Care One Prescribing Information (FDA)

  • Gesticare DHA Prescribing Information (FDA)

  • Gesticare DHA MedFacts Consumer Leaflet (Wolters Kluwer)

  • Inatal Advance Prescribing Information (FDA)

  • Inatal Ultra Prescribing Information (FDA)

  • Multi-Nate DHA Prescribing Information (FDA)

  • Multi-Nate DHA Extra Prescribing Information (FDA)

  • MultiNatal Plus MedFacts Consumer Leaflet (Wolters Kluwer)

  • Natelle One Prescribing Information (FDA)

  • Neevo Caplets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Neevo DHA MedFacts Consumer Leaflet (Wolters Kluwer)

  • OB Complete 400 MedFacts Consumer Leaflet (Wolters Kluwer)

  • Paire OB Plus DHA Prescribing Information (FDA)

  • PreNexa MedFacts Consumer Leaflet (Wolters Kluwer)

  • PreNexa Prescribing Information (FDA)

  • PreferaOB Prescribing Information (FDA)

  • Prenatal Plus Prescribing Information (FDA)

  • Prenatal Plus Iron Prescribing Information (FDA)

  • Prenate Elite Prescribing Information (FDA)

  • Prenate Elite MedFacts Consumer Leaflet (Wolters Kluwer)

  • Prenate Elite tablets

  • Prenate Essential Prescribing Information (FDA)

  • PrimaCare Advantage MedFacts Consumer Leaflet (Wolters Kluwer)

  • PrimaCare ONE capsules

  • PrimaCare One MedFacts Consumer Leaflet (Wolters Kluwer)

  • Renate DHA Prescribing Information (FDA)

  • Se-Natal 19 Chewable Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Se-Natal 19 Prescribing Information (FDA)

  • Tandem DHA Prescribing Information (FDA)

  • Tandem OB Prescribing Information (FDA)

  • TriAdvance Prescribing Information (FDA)

  • Triveen-One MedFacts Consumer Leaflet (Wolters Kluwer)

  • Triveen-PRx RNF Prescribing Information (FDA)

  • UltimateCare ONE NF Prescribing Information (FDA)

  • Ultra NatalCare MedFacts Consumer Leaflet (Wolters Kluwer)

  • Vinate AZ Prescribing Information (FDA)

  • Vitafol-One MedFacts Consumer Leaflet (Wolters Kluwer)

  • Zatean-CH Prescribing Information (FDA)



Compare Duet DHA with other medications


  • Vitamin/Mineral Supplementation during Pregnancy/Lactation


Where can I get more information?


  • Your pharmacist can provide more information about prenatal vitamins.

See also: Duet DHA side effects (in more detail)


Friday, 5 March 2010

Klonazol




Klonazol may be available in the countries listed below.


Ingredient matches for Klonazol



Fluconazole

Fluconazole is reported as an ingredient of Klonazol in the following countries:


  • Argentina

International Drug Name Search

Sunday, 21 February 2010

Flamon




Flamon may be available in the countries listed below.


Ingredient matches for Flamon



Verapamil

Verapamil hydrochloride (a derivative of Verapamil) is reported as an ingredient of Flamon in the following countries:


  • Bahrain

  • Switzerland

International Drug Name Search

Friday, 19 February 2010

Carboplatino Hospira




Carboplatino Hospira may be available in the countries listed below.


Ingredient matches for Carboplatino Hospira



Carboplatin

Carboplatin is reported as an ingredient of Carboplatino Hospira in the following countries:


  • Italy

International Drug Name Search

Thursday, 18 February 2010

Protaphane Penfill




Protaphane Penfill may be available in the countries listed below.


Ingredient matches for Protaphane Penfill



Insulin, Isophane

Insulin, Isophane human (a derivative of Insulin, Isophane) is reported as an ingredient of Protaphane Penfill in the following countries:


  • Germany

  • New Zealand

International Drug Name Search

Degraspasmin




Degraspasmin may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Degraspasmin



Isoxsuprine

Isoxsuprine hydrochloride (a derivative of Isoxsuprine) is reported as an ingredient of Degraspasmin in the following countries:


  • Switzerland

International Drug Name Search

Thursday, 4 February 2010

Strepto-Penicillin




Strepto-Penicillin may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Strepto-Penicillin



Benzylpenicillin

Benzylpenicillin procaine (a derivative of Benzylpenicillin) is reported as an ingredient of Strepto-Penicillin in the following countries:


  • Switzerland

Dihydrostreptomycin

Dihydrostreptomycin sulfate (a derivative of Dihydrostreptomycin) is reported as an ingredient of Strepto-Penicillin in the following countries:


  • Switzerland

International Drug Name Search

Saturday, 23 January 2010

Ciprofloxacino Normon




Ciprofloxacino Normon may be available in the countries listed below.


Ingredient matches for Ciprofloxacino Normon



Ciprofloxacin

Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Ciprofloxacino Normon in the following countries:


  • Costa Rica

  • Dominican Republic

  • El Salvador

  • Guatemala

  • Honduras

  • Nicaragua

  • Panama

  • Spain

Ciprofloxacin lactate (a derivative of Ciprofloxacin) is reported as an ingredient of Ciprofloxacino Normon in the following countries:


  • Costa Rica

  • Dominican Republic

  • El Salvador

  • Guatemala

  • Honduras

  • Nicaragua

  • Panama

  • Spain

International Drug Name Search

Thursday, 21 January 2010

Xylacare




Xylacare may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Xylacare



Xylazine

Xylazine is reported as an ingredient of Xylacare in the following countries:


  • United Kingdom

International Drug Name Search

Saturday, 16 January 2010

Amizin GMP




Amizin GMP may be available in the countries listed below.


Ingredient matches for Amizin GMP



Azithromycin

Azithromycin is reported as an ingredient of Amizin GMP in the following countries:


  • Venezuela

International Drug Name Search

Thursday, 14 January 2010

Pendrex




Pendrex may be available in the countries listed below.


Ingredient matches for Pendrex



Perindopril

Perindopril is reported as an ingredient of Pendrex in the following countries:


  • Ireland

International Drug Name Search

Friday, 1 January 2010

Flomax




In the US, Flomax (tamsulosin systemic) is a member of the drug class antiadrenergic agents, peripherally acting and is used to treat Benign Prostatic Hyperplasia, Overactive Bladder and Urinary Tract Stones.

US matches:

  • Flomax

Ingredient matches for Flomax



Morniflumate

Morniflumate is reported as an ingredient of Flomax in the following countries:


  • Italy

Tamsulosin

Tamsulosin is reported as an ingredient of Flomax in the following countries:


  • United States

Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Flomax in the following countries:


  • Canada

  • South Africa

  • Turkey

  • United States

International Drug Name Search